182 related articles for article (PubMed ID: 14529151)
1. Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation.
Ullmann AJ; Hess G; Kolbe K; Friedrich-Freksa A; Meyer RG; Gschaidmeier H; Huber C; Fischer T
Keio J Med; 2003 Sep; 52(3):182-8. PubMed ID: 14529151
[TBL] [Abstract][Full Text] [Related]
2. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
3. Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation.
Agis H; Mannhalter C; Sperr WR; Keil F; Kalhs P; Pirc-Danoewinata H; Krauth MT; Haas OA; Geissler K; Lechner K; Valent P
Leuk Lymphoma; 2004 Jul; 45(7):1453-8. PubMed ID: 15359647
[TBL] [Abstract][Full Text] [Related]
4. Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.
Angstreich GR; Smith BD; Jones RJ
Curr Opin Oncol; 2004 Mar; 16(2):95-9. PubMed ID: 15075898
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Thomas DA; Faderl S; Cortes J; O'Brien S; Giles FJ; Kornblau SM; Garcia-Manero G; Keating MJ; Andreeff M; Jeha S; Beran M; Verstovsek S; Pierce S; Letvak L; Salvado A; Champlin R; Talpaz M; Kantarjian H
Blood; 2004 Jun; 103(12):4396-407. PubMed ID: 14551133
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
Shimoni A; Kröger N; Zander AR; Rowe JM; Hardan I; Avigdor A; Yeshurun M; Ben-Bassat I; Nagler A
Leukemia; 2003 Feb; 17(2):290-7. PubMed ID: 12592325
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate in conjunction with allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome positive leukemias: report of 4 cases.
Yamada M; Miyamura K; Fujiwara T; Yokoyama H; Tomiya Y; Ishizawa K; Harigae H; Kameoka J; Sasaki T
Tohoku J Exp Med; 2004 Sep; 204(1):79-84. PubMed ID: 15329466
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Kantarjian HM; O'Brien S; Cortes JE; Giralt SA; Rios MB; Shan J; Giles FJ; Thomas DA; Faderl S; De Lima M; Garcia-Manero G; Champlin R; Arlinghaus R; Talpaz M
Blood; 2002 Sep; 100(5):1590-5. PubMed ID: 12176876
[TBL] [Abstract][Full Text] [Related]
9. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Wassmann B; Pfeifer H; Stadler M; Bornhaüser M; Bug G; Scheuring UJ; Brück P; Stelljes M; Schwerdtfeger R; Basara N; Perz J; Bunjes D; Ledderose G; Mahlberg R; Binckebanck A; Gschaidmeier H; Hoelzer D; Ottmann OG
Blood; 2005 Jul; 106(2):458-63. PubMed ID: 15817679
[TBL] [Abstract][Full Text] [Related]
10. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.
Olavarria E; Craddock C; Dazzi F; Marin D; Marktel S; Apperley JF; Goldman JM
Blood; 2002 May; 99(10):3861-2. PubMed ID: 11986250
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim DW; Kim YJ; Chung NG; Kim YL; Hwang JY; Kim CC
Blood; 2003 Oct; 102(8):3068-70. PubMed ID: 12842984
[TBL] [Abstract][Full Text] [Related]
13. [Results up to now of administration of STI-571 (Glivec) in recurrence after allogenic and autologous stem cell transplantation in chronic myeloid leukemia].
Fischer T
Med Klin (Munich); 2002 Jan; 97 Suppl 1():22-7. PubMed ID: 11831068
[TBL] [Abstract][Full Text] [Related]
14. [Sustained complete molecular remission after cessation of imatinib mesylate treatment in a patient with relapsed chronic myelogenous leukemia after allogeneic stem cell transplantation].
Igarashi T; Hayashi T; Yasui H; Ikeda H; Takahashi T; Ishida T; Shinomura Y
Rinsho Ketsueki; 2012 Feb; 53(2):215-8. PubMed ID: 22450581
[TBL] [Abstract][Full Text] [Related]
15. [Treatment efficacy of imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in chronic phase].
Gao GL; Xu N; Zhou X; Xiao YJ; Ding L; Lu QS; Wei YQ; Zhang Y; Xu D; Sun J; Liu QF; Liu XL
Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(38):3035-9. PubMed ID: 24417923
[TBL] [Abstract][Full Text] [Related]
16. Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging.
Kreuzer KA; Klühs C; Baskaynak G; Movassaghi K; Dörken B; le Coutre P
Br J Haematol; 2004 Jan; 124(2):195-9. PubMed ID: 14687030
[TBL] [Abstract][Full Text] [Related]
17. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia.
Bhatt VR; Akhtari M; Bociek RG; Sanmann JN; Yuan J; Dave BJ; Sanger WG; Kessinger A; Armitage JO
J Natl Compr Canc Netw; 2014 Jul; 12(7):963-8. PubMed ID: 24994916
[TBL] [Abstract][Full Text] [Related]
19. Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.
Oliveira GA; Costa ES; Freitas MS; Dutra FF; Maia SF; Guerra MC; Tabernero MD; Borojevic R; Otazu IB; Silva JL
Braz J Med Biol Res; 2010 Jun; 43(6):580-4. PubMed ID: 20396859
[TBL] [Abstract][Full Text] [Related]
20. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
Simon W; Segel GB; Lichtman MA
Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
